SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG’s Tasigna Surpasses Glivec In Leukemia Treatment

June 4, 2010 | 
1 min read
ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis (NOVN.VX) said 18-month results from a study confirmed its Tasigna cancer drug is more efficient in slowing down chronic myeloid leukaemia (CLM) than older medicine Glivec.
Clinical research Phase 3
Novartis
MORE ON THIS TOPIC
Blank paper notes attached by adhesive tape, white background, vector eps10 illustration
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
 · 
2 min read
 · 
Gabrielle Masson
Killer Whale, orcinus orca, Adult Leaping, Canada
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
 · 
2 min read
 · 
Heather McKenzie
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst